A 6-month, randomized, double-blind, placebo-controlled, multicenter, safety, tolerability, and efficacy study of 3 doses of lecozotan (SRA-333) SR in outpatients with mild to moderate Alzheimer's disease treated with a cholinesterase inhibitor

Trial Profile

A 6-month, randomized, double-blind, placebo-controlled, multicenter, safety, tolerability, and efficacy study of 3 doses of lecozotan (SRA-333) SR in outpatients with mild to moderate Alzheimer's disease treated with a cholinesterase inhibitor

Completed
Phase of Trial: Phase II/III

Latest Information Update: 19 Jul 2012

At a glance

  • Drugs Lecozotan (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Jul 2012 Results presented in combination with results from the 201 study at the 2012 International Conference on Alzheimer's Disease.
    • 19 Jul 2012 Patient numbers changed to 340 as reported in the conference abstract
    • 22 Jun 2012 Planned patient number of the extension trial (EudraCT2005-001478-28) is 200 as reported by European Clinical Trials Database
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top